The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia

Leukemia

Volumn 23, Issue 3, 2009, Pages 519-527

  Giannopoulos, K ^a,b   Mertens, D ^a,c   Buhler A ^a   Barth, T F E ^a   Idler, I ^a,c   Moller P ^a   Krober A ^a   Greiner, J ^a   Chocholska, S ^b   Dmoszynska A ^b   Rolinski J ^b   Dohner H ^a   Stilgenbauer, S ^a   Schmitt, M ^a  

^a UNIVERSITY OF ULM   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; EPITOPE; IMMUNOGLOBULIN HEAVY CHAIN; KI 67 ANTIGEN; LEUKEMIA ANTIGEN; RECEPTOR FOR HYALURONIC ACID MEDIATED MOTILITY ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TARGET CELL;

EID: 62549088264     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.338     Document Type: Article

References (24)

1. Montserrat E. New prognostic markers in CLL. Hematol Am Soc Hematol Educ Program 2006, 279-284.
2. Greiner J, Li L, Ringhoffer M, Barth TF, Giannopoulos K, Guillaume P et al. Identification and characterization of epitopes of the receptor for hyaluronic acid mediated motility (RHAMM/CD168) recognized by CD8 positive T cells of HLA-A2 positive patients with acute myeloid leukemia. Blood 2005; 106: 938-945.
3. Schmitt M, Li L, Giannopoulos K, Chen J, Brunner C, Barth T et al. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Exp Hematol 2006; 34: 1709-1719.
4. Giannopoulos K, Li L, Bojarska-Junak A, Rolinski J, Dmoszynska A, Hus I et al. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol 2006; 29: 95-103.
5. Crainie M, Belch AR, Mant MJ, Pilarski L. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clones in multiple myeloma: Identification of three distinct RHAMM variants. Blood 1999; 93: 1684-1696.
6. Assmann V, Marshal JF, Fieber C, Hofmann M, Hart IR. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. J Cell Sci 1998; 111: 1685-1694.
7. Molica S, Vitelli G, Levato D, Giannarelli D, Gandolfo GM. Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression. Cancer 2001; 92: 713-719.
8. Eisterer W, Bechter O, Soderberg O, Nilsson K, Terol M, Greil R et al Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia. Leuk Res 2004; 28: 1043-1051.
9. Savani RC, Cao G, Pooler PM, Zaman A, Zhou Z, DeLisser HM. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J Biol Chem 2001; 276: 36770-36778.
10. Krober A, Bloehdorn J, Hafner S, Buhler A, Seiler T, Kienle D et al Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 969-975.
11. Krober A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P et al V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100 1410-1416.
12. Bojarska-Junak A, Giannopoulos K, Kowal M, Dmoszynska A, Rolinski J. Comparison of methods for determining zeta-chain associated protein-70 (ZAP-70) expression in patients with B-cell chronic lymphocytic leukemia (B-CLL). Cytometry B Clin Cytom 2006; 70: 293-301.
13. Britten CM, Gouttefangeas C, Schoenmaekers-Welters MJP, Pawelec G, Koch S, Ottensmeier C et al. The CIMT Monitoring Panel: Enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 2007; 56: 406-407.
14. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M et al Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2777-2783.
15. Giannopoulos K, Dmoszynñska A, Roliñski J, Hus I, Schmitt M. The expression of survivin in patients with B-cell chronic lymphocytic leukemia (B-CLL). Acta Haemat Pol 2005; 36: 83-88.
16. Bryant RJ, Banks PM, O'Malley DP. Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders. Histopathology 2006; 48: 505-515.
17. Fluckiger AC, Rossi JF, Bussel A, Bryon P, Banchereau J, Defrance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992; 80 3173-3181.
18. Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, Strachan E et al RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 2004; 104: 1151-1158.
19. Assmann V, Gillett CE, Poulsom R, Ryder K, Hart IR, Hanby AM. The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells. J Pathol 2001; 195: 191-196.
20. Lugli A, Zlobec I, Gunthert U, Minoo P, Baker K, Tornillo L et al. Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer. Mod Pathol 2006; 19: 1302-1309.
21. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A et al Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006; 108: 4109-4117.
22. Mohapatra S, Yang X, Wright JA, Turley EA, Greenberg AH. Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J Exp Med 1996; 183: 1663-1668.
23. Maxwell CA, Keats JJ, Crainie M, Sun X, Yen T, Shibuya E et al. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell 2003; 14: 2262-2276.
24. Chiorazzi N, Ferrarini M. Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. Hematol Am Soc Hematol Educ Program 2006, 273-278.